Pasithea Therapeutics Corp (KTTA) Price & Analysis

Compare

146 Followers

KTTA Stock Chart & Stats

$0.85

-$0.19(-6.35%)

At close: Jan 08 4:00 PM EST

$0.85

-$0.19(-6.35%)

Day’s Range― - ―

52-Week Range$0.28 - $3.79

Previous CloseN/A

Volume25.24K

Average Volume (3M)98.68K

Market Cap

$19.58M

Enterprise Value$2.03M

Total Cash (Recent Filing)$4.12M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta4.20

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding23,091,063

10 Day Avg. Volume100,274

30 Day Avg. Volume98,683

Financial Highlights & Ratios

PEG Ratio-0.79

Price to Book (P/B)0.23

Price to Sales (P/S)0.00

P/FCF Ratio-0.25

Enterprise Value/Market Cap0.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.92

Enterprise Value/Ebitda-0.16

Forecast

1Y Price Target

$3.00

Price Target Upside252.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet And FinancingA financing strengthened the company's balance sheet, providing resources and flexibility to advance multiple clinical programs and reduce near-term funding pressure.

Clinical Data CatalystsPlanned clinical data releases from completed early cohorts in the Phase 1/1b NF1-PN study could materially clarify PAS-004's safety and efficacy and influence company valuation.

Compound DifferentiationAnalyst highlights PAS-004's macrocyclic design as intended to improve target binding, selectivity, and oral bioavailability relative to earlier MEK inhibitors, potentially enhancing its clinical profile.

Bears Say

Clinical Development RiskThe clinical burden and heterogeneity of NF1 tumors may make it difficult for PAS-004 to demonstrate clear, consistent efficacy across patients, increasing development risk.

Endpoint UncertaintyComplex symptom profiles in NF1-associated tumors can complicate selection and measurement of meaningful trial endpoints, raising the risk that data may be inconclusive.

Enrollment And Trial ExecutionHigh clinical burden among NF1 patients could limit patient availability or produce heterogeneous enrollment, which may slow trials or obscure clinically meaningful outcomes.

Pasithea Therapeutics Corp News

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

Pasithea Therapeutics Corp ( ($KTTA) ) has provided an update. On February 20, 2026, Pasithea Therapeutics received a...

20d ago

KTTA

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On January 28, 2026, Pasithea Therapeutics...

1M ago

KTTA

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Pasithea Therapeutics Corp, retaining the price target...

2M ago

KTTA

Pasithea Therapeutics provides updated timeline on PAS-004 programs

Pasithea Therapeutics (KTTA) provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients....

2M ago

KTTA

Pasithea Therapeutics Regains Nasdaq Compliance

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an announcement. Pasithea Therapeutics Corp. announced that it has regained...

3M ago

KTTA

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics (KTTA) with a Buy rating and $3 price...

3M ago

KTTA

3 Penny Stocks to Watch Now, 12/2/25

Pasithea Therapeutics ($KTTA), Aditxt ($ADTX), and HeartBeam ($BEAT) are the 3 Penny Stocks to watch on December 2, 2025, based...

3M ago

ADTX

BEAM

Pasithea Therapeutics Completes $60M Public Offering

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. On November 28, 2025, Pasithea Therapeutics Corp announced...

3M ago

KTTA

Pasithea Therapeutics prices 80M shares at 75c in public offering

Pasithea Therapeutics (KTTA) announced the pricing of a public offering of 80,000,000 shares of the Company’s common stock...

3M ago

KTTA

3 Penny Stocks to Watch Now, 11/27/25

Zynex Inc., Amber International Holding, and Pasithea Therapeutics are the 3 Penny Stocks to watch on November 27, 2025, based...

4M ago

AMBR

KTTA

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. Pasithea Therapeutics announced positive interim Phase 1 data...

4M ago

KTTA

Pasithea Therapeutics announces $1M award by ALS Association

Pasithea Therapeutics (KTTA) announced that the ALS Association has awarded a Hoffman ALS Clinical Trial Award grant worth...

4M ago

KTTA

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

Pasithea Therapeutics (KTTA) announced safety, PK and PD data from Cohort 7 in its ongoing first-in-human trial evaluating...

4M ago

KTTA

Pasithea says tablet PK exposure increases proprtionally with dose increase

Pasithea Therapeutics (KTTA) announced tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients...

4M ago

KTTA

KTTA FAQ

What was Pasithea Therapeutics Corp’s price range in the past 12 months?

Pasithea Therapeutics Corp lowest stock price was $0.28 and its highest was $3.79 in the past 12 months.

What is Pasithea Therapeutics Corp’s market cap?

Pasithea Therapeutics Corp’s market cap is $19.58M.

When is Pasithea Therapeutics Corp’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pasithea Therapeutics Corp’s earnings last quarter?

Currently, no data Available

Is Pasithea Therapeutics Corp overvalued?

According to Wall Street analysts Pasithea Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pasithea Therapeutics Corp pay dividends?

Pasithea Therapeutics Corp does not currently pay dividends.

What is Pasithea Therapeutics Corp’s EPS estimate?

Pasithea Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pasithea Therapeutics Corp have?

Pasithea Therapeutics Corp has 23,091,063 shares outstanding.

What happened to Pasithea Therapeutics Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pasithea Therapeutics Corp?

Currently, no hedge funds are holding shares in KTTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp (KTTA) Earnings & Revenues

Historic Earnings Reports

KTTA Stock 12 Month Forecast

Average Price Target

$3.00

▲(252.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","67":"$67","16.75":"$16.75","33.5":"$33.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,16.75,33.5,50.25,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2021","6":"Nov<br/>2021","9":"Aug<br/>2022","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.4215384615384616,1.5530769230769232,1.6846153846153846,1.8161538461538462,1.9476923076923078,2.079230769230769,2.210769230769231,2.3423076923076924,2.473846153846154,2.6053846153846156,2.736923076923077,2.8684615384615384,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.4215384615384616,1.5530769230769232,1.6846153846153846,1.8161538461538462,1.9476923076923078,2.079230769230769,2.210769230769231,2.3423076923076924,2.473846153846154,2.6053846153846156,2.736923076923077,2.8684615384615384,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.4215384615384616,1.5530769230769232,1.6846153846153846,1.8161538461538462,1.9476923076923078,2.079230769230769,2.210769230769231,2.3423076923076924,2.473846153846154,2.6053846153846156,2.736923076923077,2.8684615384615384,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.2,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.2,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66,"date":1638316800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >